Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Cell Therapy In Dilated Cardiomyopathy

This study has been completed.
Financiadora de Estudos e Projetos
Information provided by (Responsible Party):
Bernardo Rangel Tura, Ministry of Health, Brazil Identifier:
First received: June 5, 2006
Last updated: March 9, 2017
Last verified: March 2017
The purpose of this study is to determine effect of cell therapy in patients with severe dilated cardiomyopathy

Condition Intervention Phase
Dilated Cardiomyopathy
Drug: optimal therapy for cardiaca failure
Procedure: cell
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Treatment
Official Title: Multicenter Randomized Study Of Cell Therapy In Cardiopathies - Dilated Cardiomyopathy

Resource links provided by NLM:

Further study details as provided by Bernardo Rangel Tura, Ministry of Health, Brazil:

Primary Outcome Measures:
  • increase of the ejection fraction of the left ventricle [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Death by any cause [ Time Frame: 1 year ]
  • Maximum oxygen consumption difference, as measured by ergoespirometry, at six and twelve months in relation to baseline [ Time Frame: 1 year ]
  • Difference in life quality as estimated by Minnesota living with Heart Failure Questionnaire [ Time Frame: 6 month ]
  • Difference in NYHA functional class [ Time Frame: 6 month ]
  • Percent number of patients that reached an absolute increase of 5% in ejection fraction [ Time Frame: 1 year ]

Enrollment: 115
Study Start Date: January 2006
Study Completion Date: February 2013
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Optimal Therapy
Optimal therapy for cardiac failure
Drug: optimal therapy for cardiaca failure
optimal therapy for cardiaca failure
Experimental: cell therapy
stem cell
Procedure: cell
stem cell

Detailed Description:

This protocol describes a double-blind placebo controlled randomized clinical trial to evaluate the efficacy of bone marrow derived stem cell implants in 300 bazillion patients with dilated cardiomyopathy and heart failure in class III or IV of the New York Heart Association.

The primary endpoint of this study is to evaluate the effect of the autologous bone marrow stem cell implant in the increase of the ejection fraction of the left ventricle in comparison with a control group, under optimized therapy for dilated cardiomyopathy. Secondary endpoints will evaluate the alteration in NYHA functional class, mortality rate, physical capacity (by ergoespirometry), life quality (Minnesota questionnaire) and pulmonary congestion in dilated cardiomyopathy patients the received the autologous bone-marrow stem cell implant.

Hypothesis: The main hypothesis of this study is that the patients who received the autologous bone-marrow stem cell implant will have after a 6 month follow-up a mean 5% increase in absolute left ventricle ejection fraction in comparison with the control group.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of dilated cardiomyopathy according to WHO criteria
  • Syndromic heart failure in functional class III or IV of the NYHA
  • Enrollment and continuous follow-up in cardiac out-patient clinic
  • Adequate medical therapy after optimization therapy
  • Echocardiogram with an ejection fraction equal to or less than 35% by Simpson's rule

Exclusion Criteria:

  • Valvular diseases, except functional mitral or tricuspid reflow
  • Coronariography showing a significant lesion (obstruction of at least 50% of the lumen in the troncus or the main arteries - LAD, CX, RC) in one or more arteries
  • Serologic diagnosis for Chagas disease or at least two of the following criteria: epidemiology, right bundle branch block, anterior hemi-block, apical aneurism
  • Sustained ventricular tachycardia
  • Abusive use of alcohol or illicit drugs
  • Pregnancy
  • Use of cardio toxic drugs
  • Any co-morbidity with impact in life expectancy in 2 years
  • Renal function compromised (creatinine above 2 mg/dl)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00333827

INCL - National Institute of Cardiology Laranjeiras
Rio de Janeiro, Brazil, 22.240-006
Sponsors and Collaborators
Ministry of Health, Brazil
Financiadora de Estudos e Projetos
Study Director: Antonio Carlos C de Carvalho, MD,PhD INCL
Study Chair: Bernardo R Tura, Md,MsC INCL
Principal Investigator: Augusto Z Bozza, MD INCL
  More Information

Additional Information:
Responsible Party: Bernardo Rangel Tura, Professor, Ministry of Health, Brazil Identifier: NCT00333827     History of Changes
Other Study ID Numbers: EMRTCC-MCD
Study First Received: June 5, 2006
Last Updated: March 9, 2017

Keywords provided by Bernardo Rangel Tura, Ministry of Health, Brazil:
Dilated Cardiomyopathy
stem cells
Randomized Controlled Trials

Additional relevant MeSH terms:
Cardiomyopathy, Dilated
Heart Diseases
Cardiovascular Diseases
Cardiomegaly processed this record on May 25, 2017